医学
随机对照试验
溶栓
麻醉
心脏病学
内科学
梅德林
心肌梗塞
血压
缺血
外科
临床试验
血流动力学
纤溶剂
作者
Long Wang,Chi Zhang,Dun-Ling Li,Jie Hu,Yu Wang,Qiu-wan Liu,Jia Li,Yuan-yuan Huang,Fuyu Wang,Jun-Cang Wu
标识
DOI:10.1186/s40001-026-05071-8
摘要
To assess the safety and efficacy of enhanced external counterpulsation (EECP) when applied early after intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). AIS patients who received IVT were randomly assigned in a 1:1 ratio to the EECP group or the sham-EECP group. EECP (or sham-EECP) was initially performed within 24 h following IVT and continued with daily 30 min sessions for a subsequent period of 10 days. All participants were followed up for a 90-day period. Feasibility was assessed based on the percentage of patients who completed all scheduled EECP treatments following IVT, as well as the percentage of patients for whom EECP was discontinued at the request of doctors or nurses due to potential interference with other treatments. The safety outcomes included the incidence of early neurological deterioration (END), any hemorrhagic transformation (HT), changes in vital signs, and adverse events that occurred during the follow-up period. The effectiveness evaluation was conducted using the modified Rankin Scale (mRS) at 90 days post-treatment. Seventy-three patients (37 in the EECP group and 36 in the sham-EECP group) completed the entire study. No statistically significant differences were observed between the two groups with respect to demographic characteristics or baseline clinical parameters at admission. The median mRS score in the EECP group was significantly lower than that of Sham-EECP group (0 [IQR: 0–1] vs. 1 [IQR: 0–2]; p=0.03), indicating early EECP intervention may enhance functional outcomes in AIS patients receiving IVT. Among all randomized patients, no significant differences were observed in the incidence of serious adverse events, including END and sICH. Treatment-related adverse events such as headache or dizziness during therapy and/or lumbago were reported in four patients (10.8%) and 2 patients (5.6%), respectively, in the EECP group and sham-EECP group. This pilot study indicates that EECP may be both safe and potentially beneficial for AIS patients receiving IVT. Further larger-scale, prospective studies are needed to verify the efficacy of EECP in this population. Clinical trial registration and registry URL ChiCTR2400080746, registered at www. chictr. org. cn, 2024/2/6.
科研通智能强力驱动
Strongly Powered by AbleSci AI